�Boston Scientific Corporation proclaimed the number one UK implants of its next-generation inwardness devices - the COGNIS� cardiac resynchronisation therapy defibrillator (CRT-D) and TELIGEN� implantable cardioverter defibrillator (ICD). These devices defend entirely new platforms to treat fondness failure and sudden cardiac death. Both products standard CE Mark approval originally this year.
Physicians in the UK began implanting the COGNIS and TELIGEN devices in July.
"Around 2.6 million people in the UK ar living with heart disease," said Mark Harty, UK and Ireland General Manager, Boston Scientific. "When choosing a high-voltage device, physicians often must make trade-offs among gimmick size, battery longevity and features. The COGNIS CRT-D and the TELIGEN ICD are designed to eliminate those compromises."
The matchbox sized devices detect irregular heart beats and then try to correct the rhythm with small controlled electric shocks. If this fails then a
